FOXP3 and myeloid sarcoma: A phase-2 trial with a monoclonal anti-CD4 antibody failed to diminish MS pathology [172], possibly due to CD4+Foxp3+ Tregs playing a crucial function in inhibiting autoreactive T-cell activity [97].